Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARCT shares.
View ARCT analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued twelve-month price targets for Arcturus Therapeutics' shares. Their ARCT share price targets range from $45.00 to $90.00. On average, they expect the company's share price to reach $61.33 in the next year. This suggests a possible upside of 136.1% from the stock's current price.
View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts.

Arcturus Therapeutics' stock was trading at $31.53 on January 1st, 2024. Since then, ARCT shares have decreased by 17.6% and is now trading at $25.98.
View the best growth stocks for 2024 here.

Arcturus Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,810,000 shares, an increase of 14.3% from the March 15th total of 4,210,000 shares. Based on an average trading volume of 454,500 shares, the short-interest ratio is presently 10.6 days. Approximately 19.6% of the shares of the stock are short sold.
View Arcturus Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARCT earnings forecast.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings results on Thursday, March, 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $1.37. The biotechnology company earned $33.99 million during the quarter, compared to analyst estimates of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative trailing twelve-month return on equity of 18.22%.

ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG), WisdomTree BioRevolution Fund (WDNA), Amplify Treatments, Testing and Advancements ETF (GERM), AXS Green Alpha ETF (NXTE), Jacob Forward ETF (JFWD) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

Arcturus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (4.74%), Hennion & Walsh Asset Management Inc. (0.12%), Allspring Global Investments Holdings LLC (0.11%) and Denali Advisors LLC (0.02%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends.

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.